Tempest Therapeutics Inc
TPST
Company Profile
Business description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
Contact
2000 Sierra Point Parkway
Suite 400
BrisbaneCA94005
USAT: +1 415 798-8589
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
Shares trade at a discount despite attractive longer-term outlook.
stocks
The ultimate investing hack: dividend growth stocks
Finding companies built for lasting dividend growth.
stocks
Is the data centre party over for Goodman?
Global spending spree on data centres could mean a declining return on invested capital.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,906.70 | 9.80 | -0.11% |
| CAC 40 | 8,122.03 | 34.61 | 0.43% |
| DAX 40 | 23,882.03 | 188.32 | 0.79% |
| Dow JONES (US) | 47,850.94 | 31.96 | -0.07% |
| FTSE 100 | 9,710.87 | 18.80 | 0.19% |
| HKSE | 25,935.90 | 175.17 | 0.68% |
| NASDAQ | 23,505.14 | 51.04 | 0.22% |
| Nikkei 225 | 51,028.42 | 1,163.74 | 2.33% |
| NZX 50 Index | 13,460.49 | 55.13 | -0.41% |
| S&P 500 | 6,857.12 | 7.40 | 0.11% |
| S&P/ASX 200 | 8,618.40 | 0.40 | -0.00% |
| SSE Composite Index | 3,875.79 | 2.21 | -0.06% |